Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Squamous Cell Carcinoma of Head and Neck 3 Head and Neck Neoplasms 2 Carcinoma, Squamous Cell 2 Carcinoma, Non-Small-Cell Lung 2 Tongue Neoplasms 1 Salivary Gland Neoplasms 1 Recurrence 1 Neoplasms 1 Nasopharyngeal Carcinoma 1 Lung Neoplasms 1 Klatskin Tumor 1 Cholangiocarcinoma 1 Carcinoma, Large Cell 1 Adenocarcinoma 1

Interventions

Cisplatin 127 Gemcitabine 71 Radiotherapy, Intensity-Modulated 61 toripalimab 39 Capecitabine 37 Docetaxel 36 Fluorouracil 35 Radiotherapy 24 camrelizumab 23 Drug Therapy 22 nimotuzumab 18 spartalizumab 13 pembrolizumab 13 nedaplatin 12 Chemoradiotherapy 12 sintilimab 11 apatinib 11 Induction Chemotherapy 11 Immune Checkpoint Inhibitors 11 tislelizumab 10 Nivolumab 10 Magnetic Resonance Spectroscopy 10 Specimen Handling 9 Radiation 9 Cetuximab 9 Carboplatin 9 endostar protein 8 Paclitaxel 8 Bevacizumab 8 anlotinib 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Nasopharyngeal Carcinoma × temoporfin × Clear all

NCT01086488 2011-07-08

FOSCAN

Ministry of Health, Malaysia

Phase 2 Unknown

Nasopharyngeal Carcinoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡